questionsmedicales.fr
Composés hétérocycliques
Composés hétérocycliques à cycles fusionnés
Composés hétérobicycliques
Benzazépines
Benzodiazépines
Benzodiazépines : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Benzodiazépines : Questions médicales les plus fréquentes",
"headline": "Benzodiazépines : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Benzodiazépines : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-02-04",
"dateModified": "2025-04-29",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Benzodiazépines"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Benzazépines",
"url": "https://questionsmedicales.fr/mesh/D001552",
"about": {
"@type": "MedicalCondition",
"name": "Benzazépines",
"code": {
"@type": "MedicalCode",
"code": "D001552",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Alprazolam",
"alternateName": "Alprazolam",
"url": "https://questionsmedicales.fr/mesh/D000525",
"about": {
"@type": "MedicalCondition",
"name": "Alprazolam",
"code": {
"@type": "MedicalCode",
"code": "D000525",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.030"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Benzodiazépinones",
"alternateName": "Benzodiazepinones",
"url": "https://questionsmedicales.fr/mesh/D001570",
"about": {
"@type": "MedicalCondition",
"name": "Benzodiazépinones",
"code": {
"@type": "MedicalCode",
"code": "D001570",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.070"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Bromazépam",
"alternateName": "Bromazepam",
"url": "https://questionsmedicales.fr/mesh/D001960",
"about": {
"@type": "MedicalCondition",
"name": "Bromazépam",
"code": {
"@type": "MedicalCode",
"code": "D001960",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.070.110"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Clonazépam",
"alternateName": "Clonazepam",
"url": "https://questionsmedicales.fr/mesh/D002998",
"about": {
"@type": "MedicalCondition",
"name": "Clonazépam",
"code": {
"@type": "MedicalCode",
"code": "D002998",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.070.150"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Dévazépide",
"alternateName": "Devazepide",
"url": "https://questionsmedicales.fr/mesh/D020109",
"about": {
"@type": "MedicalCondition",
"name": "Dévazépide",
"code": {
"@type": "MedicalCode",
"code": "D020109",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.070.200"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Diazépam",
"alternateName": "Diazepam",
"url": "https://questionsmedicales.fr/mesh/D003975",
"about": {
"@type": "MedicalCondition",
"name": "Diazépam",
"code": {
"@type": "MedicalCode",
"code": "D003975",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.070.216"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Nordazépam",
"alternateName": "Nordazepam",
"url": "https://questionsmedicales.fr/mesh/D003708",
"about": {
"@type": "MedicalCondition",
"name": "Nordazépam",
"code": {
"@type": "MedicalCode",
"code": "D003708",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.070.216.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Nordazépam",
"alternateName": "Nordazepam",
"url": "https://questionsmedicales.fr/mesh/D003708",
"about": {
"@type": "MedicalCondition",
"name": "Nordazépam",
"code": {
"@type": "MedicalCode",
"code": "D003708",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.070.216.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Flumazénil",
"alternateName": "Flumazenil",
"url": "https://questionsmedicales.fr/mesh/D005442",
"about": {
"@type": "MedicalCondition",
"name": "Flumazénil",
"code": {
"@type": "MedicalCode",
"code": "D005442",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.070.305"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Flunitrazépam",
"alternateName": "Flunitrazepam",
"url": "https://questionsmedicales.fr/mesh/D005445",
"about": {
"@type": "MedicalCondition",
"name": "Flunitrazépam",
"code": {
"@type": "MedicalCode",
"code": "D005445",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.070.320"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Flurazépam",
"alternateName": "Flurazepam",
"url": "https://questionsmedicales.fr/mesh/D005479",
"about": {
"@type": "MedicalCondition",
"name": "Flurazépam",
"code": {
"@type": "MedicalCode",
"code": "D005479",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.070.348"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Lorazépam",
"alternateName": "Lorazepam",
"url": "https://questionsmedicales.fr/mesh/D008140",
"about": {
"@type": "MedicalCondition",
"name": "Lorazépam",
"code": {
"@type": "MedicalCode",
"code": "D008140",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.070.450"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Nitrazépam",
"alternateName": "Nitrazepam",
"url": "https://questionsmedicales.fr/mesh/D009567",
"about": {
"@type": "MedicalCondition",
"name": "Nitrazépam",
"code": {
"@type": "MedicalCode",
"code": "D009567",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.070.565"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Oxazépam",
"alternateName": "Oxazepam",
"url": "https://questionsmedicales.fr/mesh/D010076",
"about": {
"@type": "MedicalCondition",
"name": "Oxazépam",
"code": {
"@type": "MedicalCode",
"code": "D010076",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.070.663"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Pirenzépine",
"alternateName": "Pirenzepine",
"url": "https://questionsmedicales.fr/mesh/D010890",
"about": {
"@type": "MedicalCondition",
"name": "Pirenzépine",
"code": {
"@type": "MedicalCode",
"code": "D010890",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.070.750"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Prazépam",
"alternateName": "Prazepam",
"url": "https://questionsmedicales.fr/mesh/D011222",
"about": {
"@type": "MedicalCondition",
"name": "Prazépam",
"code": {
"@type": "MedicalCode",
"code": "D011222",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.070.784"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Témazépam",
"alternateName": "Temazepam",
"url": "https://questionsmedicales.fr/mesh/D013693",
"about": {
"@type": "MedicalCondition",
"name": "Témazépam",
"code": {
"@type": "MedicalCode",
"code": "D013693",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.070.880"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Chlordiazépoxyde",
"alternateName": "Chlordiazepoxide",
"url": "https://questionsmedicales.fr/mesh/D002707",
"about": {
"@type": "MedicalCondition",
"name": "Chlordiazépoxyde",
"code": {
"@type": "MedicalCode",
"code": "D002707",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.150"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Clobazam",
"alternateName": "Clobazam",
"url": "https://questionsmedicales.fr/mesh/D000078306",
"about": {
"@type": "MedicalCondition",
"name": "Clobazam",
"code": {
"@type": "MedicalCode",
"code": "D000078306",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.165"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Clorazépate dipotassique",
"alternateName": "Clorazepate Dipotassium",
"url": "https://questionsmedicales.fr/mesh/D003009",
"about": {
"@type": "MedicalCondition",
"name": "Clorazépate dipotassique",
"code": {
"@type": "MedicalCode",
"code": "D003009",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.180"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Estazolam",
"alternateName": "Estazolam",
"url": "https://questionsmedicales.fr/mesh/D004949",
"about": {
"@type": "MedicalCondition",
"name": "Estazolam",
"code": {
"@type": "MedicalCode",
"code": "D004949",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.250"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Médazépam",
"alternateName": "Medazepam",
"url": "https://questionsmedicales.fr/mesh/D008472",
"about": {
"@type": "MedicalCondition",
"name": "Médazépam",
"code": {
"@type": "MedicalCode",
"code": "D008472",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.550"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Midazolam",
"alternateName": "Midazolam",
"url": "https://questionsmedicales.fr/mesh/D008874",
"about": {
"@type": "MedicalCondition",
"name": "Midazolam",
"code": {
"@type": "MedicalCode",
"code": "D008874",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.575"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Olanzapine",
"alternateName": "Olanzapine",
"url": "https://questionsmedicales.fr/mesh/D000077152",
"about": {
"@type": "MedicalCondition",
"name": "Olanzapine",
"code": {
"@type": "MedicalCode",
"code": "D000077152",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.738"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Triazolam",
"alternateName": "Triazolam",
"url": "https://questionsmedicales.fr/mesh/D014229",
"about": {
"@type": "MedicalCondition",
"name": "Triazolam",
"code": {
"@type": "MedicalCode",
"code": "D014229",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D03.633.100.079.080.900"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Benzodiazépines",
"alternateName": "Benzodiazepines",
"code": {
"@type": "MedicalCode",
"code": "D001569",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Babette Bais",
"url": "https://questionsmedicales.fr/author/Babette%20Bais",
"affiliation": {
"@type": "Organization",
"name": "Department of Psychiatry, Erasmus University Medical Centre Rotterdam, Rotterdam, Netherlands."
}
},
{
"@type": "Person",
"name": "Steven Wright",
"url": "https://questionsmedicales.fr/author/Steven%20Wright",
"affiliation": {
"@type": "Organization",
"name": "Former medical director of the Alliance for Benzodiazepine Best Practices, Portland, OR, a nonprofit resource for physicians and patients."
}
},
{
"@type": "Person",
"name": "Christine Champion",
"url": "https://questionsmedicales.fr/author/Christine%20Champion",
"affiliation": {
"@type": "Organization",
"name": "Université Lyon 1, Lyon, France, Hôpital des Charpennes, Hospices Civils de Lyon, Lyon, France."
}
},
{
"@type": "Person",
"name": "Teddy Novais",
"url": "https://questionsmedicales.fr/author/Teddy%20Novais",
"affiliation": {
"@type": "Organization",
"name": "Université Lyon 1, Lyon, France, Service pharmaceutique, Hôpital des Charpennes, Hospices Civils de Lyon, Lyon, France, Université Claude-Bernard Lyon 1, Research on Healthcare Performance (RESHAPE), Inserm U1290, Lyon, France."
}
},
{
"@type": "Person",
"name": "Jean-Michel Dorey",
"url": "https://questionsmedicales.fr/author/Jean-Michel%20Dorey",
"affiliation": {
"@type": "Organization",
"name": "Université Lyon 1, Lyon, France, Centre Hospitalier Le Vinatier, Bron, France."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Low-dose esketamine with sufentanil for postcesarean analgesia in women with gestational diabetes mellitus: a prospective, randomized, double-blind study.",
"datePublished": "2023-08-11",
"url": "https://questionsmedicales.fr/article/37635978",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3389/fendo.2023.1202734"
}
},
{
"@type": "ScholarlyArticle",
"name": "Comparison of oxycodone and sufentanil in patient-controlled intravenous analgesia for postoperative patients: a meta-analysis of randomized controlled trials.",
"datePublished": "2023-01-05",
"url": "https://questionsmedicales.fr/article/36878002",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1097/CM9.0000000000002259"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sedation efficacy of different dose of remimazolam with sufentanil for nerve block in young and elderly patients: a randomized, controlled study.",
"datePublished": "2022-12-03",
"url": "https://questionsmedicales.fr/article/36462032",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s00540-022-03142-8"
}
},
{
"@type": "ScholarlyArticle",
"name": "Sufentanil for Spinal Analgesia during Cesarean Section Delivery: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.",
"datePublished": "2022-08-31",
"url": "https://questionsmedicales.fr/article/36105787",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/4741141"
}
},
{
"@type": "ScholarlyArticle",
"name": "Extrapleural infusion of levobupivacaine versus levobupivacaine-sufentanil-adrenaline after video-assisted thoracoscopic surgery (VATS): A randomised controlled trial.",
"datePublished": "2023-06-21",
"url": "https://questionsmedicales.fr/article/37344999",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/aas.14300"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Composés hétérocycliques",
"item": "https://questionsmedicales.fr/mesh/D006571"
},
{
"@type": "ListItem",
"position": 3,
"name": "Composés hétérocycliques à cycles fusionnés",
"item": "https://questionsmedicales.fr/mesh/D000072471"
},
{
"@type": "ListItem",
"position": 4,
"name": "Composés hétérobicycliques",
"item": "https://questionsmedicales.fr/mesh/D006574"
},
{
"@type": "ListItem",
"position": 5,
"name": "Benzazépines",
"item": "https://questionsmedicales.fr/mesh/D001552"
},
{
"@type": "ListItem",
"position": 6,
"name": "Benzodiazépines",
"item": "https://questionsmedicales.fr/mesh/D001569"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Benzodiazépines - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Benzodiazépines",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-05",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Benzodiazépines",
"description": "Comment diagnostiquer une dépendance aux benzodiazépines ?\nQuels tests sont utilisés pour évaluer l'usage des benzodiazépines ?\nQuels critères DSM sont utilisés pour le diagnostic ?\nComment évaluer l'efficacité d'un traitement par benzodiazépines ?\nQuels signes indiquent une surdose de benzodiazépines ?",
"url": "https://questionsmedicales.fr/mesh/D001569?mesh_terms=Sufentanil&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Benzodiazépines",
"description": "Quels sont les effets secondaires courants des benzodiazépines ?\nComment reconnaître une réaction allergique aux benzodiazépines ?\nQuels symptômes indiquent un sevrage des benzodiazépines ?\nLes benzodiazépines provoquent-elles des troubles cognitifs ?\nQuels symptômes peuvent nécessiter une consultation médicale urgente ?",
"url": "https://questionsmedicales.fr/mesh/D001569?mesh_terms=Sufentanil&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Benzodiazépines",
"description": "Comment prévenir la dépendance aux benzodiazépines ?\nQuels conseils donner aux patients sur l'utilisation des benzodiazépines ?\nComment surveiller l'utilisation des benzodiazépines ?\nQuelles stratégies non médicamenteuses peuvent aider ?\nComment sensibiliser sur les risques des benzodiazépines ?",
"url": "https://questionsmedicales.fr/mesh/D001569?mesh_terms=Sufentanil&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Benzodiazépines",
"description": "Comment traiter une dépendance aux benzodiazépines ?\nQuelles alternatives existent aux benzodiazépines pour l'anxiété ?\nComment réduire progressivement l'utilisation des benzodiazépines ?\nQuels médicaments peuvent aider à gérer le sevrage ?\nQuelle est la durée recommandée pour l'utilisation des benzodiazépines ?",
"url": "https://questionsmedicales.fr/mesh/D001569?mesh_terms=Sufentanil&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Benzodiazépines",
"description": "Quelles complications peuvent survenir avec l'usage prolongé ?\nComment les benzodiazépines affectent-elles la santé mentale ?\nQuels risques sont associés à l'association avec d'autres médicaments ?\nLes benzodiazépines peuvent-elles provoquer des chutes chez les personnes âgées ?\nQuels effets à long terme sur la mémoire sont observés ?",
"url": "https://questionsmedicales.fr/mesh/D001569?mesh_terms=Sufentanil&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Benzodiazépines",
"description": "Quels facteurs augmentent le risque de dépendance ?\nComment l'âge influence-t-il l'usage des benzodiazépines ?\nQuel rôle joue l'environnement social dans l'usage ?\nLes antécédents familiaux influencent-ils l'usage ?\nComment les troubles de santé mentale affectent-ils l'usage ?",
"url": "https://questionsmedicales.fr/mesh/D001569?mesh_terms=Sufentanil&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dépendance aux benzodiazépines ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur l'évaluation des symptômes et l'historique d'utilisation des médicaments."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer l'usage des benzodiazépines ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de dépistage de drogues et des évaluations psychologiques peuvent être utilisés."
}
},
{
"@type": "Question",
"name": "Quels critères DSM sont utilisés pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les critères DSM-5 incluent l'usage excessif et les symptômes de sevrage."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'efficacité d'un traitement par benzodiazépines ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'efficacité est évaluée par la réduction des symptômes d'anxiété ou d'insomnie."
}
},
{
"@type": "Question",
"name": "Quels signes indiquent une surdose de benzodiazépines ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent confusion, somnolence excessive et difficultés respiratoires."
}
},
{
"@type": "Question",
"name": "Quels sont les effets secondaires courants des benzodiazépines ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires incluent somnolence, vertiges et troubles de la mémoire."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une réaction allergique aux benzodiazépines ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les réactions allergiques peuvent se manifester par éruptions cutanées et démangeaisons."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un sevrage des benzodiazépines ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes de sevrage incluent anxiété, insomnie et tremblements."
}
},
{
"@type": "Question",
"name": "Les benzodiazépines provoquent-elles des troubles cognitifs ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles peuvent entraîner des troubles de la mémoire et de la concentration."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent nécessiter une consultation médicale urgente ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme confusion sévère ou difficultés respiratoires nécessitent une urgence."
}
},
{
"@type": "Question",
"name": "Comment prévenir la dépendance aux benzodiazépines ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention inclut une prescription prudente et une éducation sur les risques."
}
},
{
"@type": "Question",
"name": "Quels conseils donner aux patients sur l'utilisation des benzodiazépines ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les patients doivent être informés des risques et de l'importance de suivre les prescriptions."
}
},
{
"@type": "Question",
"name": "Comment surveiller l'utilisation des benzodiazépines ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les médecins doivent effectuer des suivis réguliers pour évaluer l'usage et les effets."
}
},
{
"@type": "Question",
"name": "Quelles stratégies non médicamenteuses peuvent aider ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des techniques comme la méditation et l'exercice physique peuvent réduire l'anxiété."
}
},
{
"@type": "Question",
"name": "Comment sensibiliser sur les risques des benzodiazépines ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des campagnes d'information et des ateliers peuvent sensibiliser le public aux risques."
}
},
{
"@type": "Question",
"name": "Comment traiter une dépendance aux benzodiazépines ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut une désintoxication supervisée et une thérapie comportementale."
}
},
{
"@type": "Question",
"name": "Quelles alternatives existent aux benzodiazépines pour l'anxiété ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les alternatives incluent les antidépresseurs et les thérapies cognitivo-comportementales."
}
},
{
"@type": "Question",
"name": "Comment réduire progressivement l'utilisation des benzodiazépines ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "La réduction doit être progressive, sous supervision médicale pour éviter le sevrage."
}
},
{
"@type": "Question",
"name": "Quels médicaments peuvent aider à gérer le sevrage ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des médicaments comme le diazépam peuvent être utilisés pour atténuer les symptômes de sevrage."
}
},
{
"@type": "Question",
"name": "Quelle est la durée recommandée pour l'utilisation des benzodiazépines ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'utilisation est généralement recommandée pour une courte durée, souvent moins de 4 semaines."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec l'usage prolongé ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'usage prolongé peut entraîner des troubles cognitifs et une dépendance sévère."
}
},
{
"@type": "Question",
"name": "Comment les benzodiazépines affectent-elles la santé mentale ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent aggraver des troubles mentaux comme la dépression et l'anxiété."
}
},
{
"@type": "Question",
"name": "Quels risques sont associés à l'association avec d'autres médicaments ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'association avec des opioïdes ou l'alcool augmente le risque de dépression respiratoire."
}
},
{
"@type": "Question",
"name": "Les benzodiazépines peuvent-elles provoquer des chutes chez les personnes âgées ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles augmentent le risque de chutes et de fractures chez les personnes âgées."
}
},
{
"@type": "Question",
"name": "Quels effets à long terme sur la mémoire sont observés ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'usage prolongé peut entraîner des troubles de la mémoire et des difficultés d'apprentissage."
}
},
{
"@type": "Question",
"name": "Quels facteurs augmentent le risque de dépendance ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les antécédents de troubles mentaux et l'usage prolongé augmentent le risque de dépendance."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il l'usage des benzodiazépines ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes âgées sont plus susceptibles de subir des effets secondaires et des complications."
}
},
{
"@type": "Question",
"name": "Quel rôle joue l'environnement social dans l'usage ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un environnement stressant ou un manque de soutien social peut augmenter l'usage des benzodiazépines."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils l'usage ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de dépendance peuvent augmenter le risque d'usage problématique."
}
},
{
"@type": "Question",
"name": "Comment les troubles de santé mentale affectent-ils l'usage ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les personnes avec des troubles de santé mentale sont plus susceptibles d'utiliser des benzodiazépines."
}
}
]
}
]
}
Pregnant women with gestational diabetes mellitus (GDM) require more analgesics after cesarean delivery than those who do not have GDM. Uncontrolled pain following cesarean delivery is a major problem...
One hundred forty pregnant women with GDM were enrolled participate in this randomized controlled trial and were randomized into two groups (70 in each group). The esketamine (S) group was given esket...
Compared with group C, group S had significantly lower sufentanil consumption at 6 and 24 hours postoperatively (P= 0.049 and P<0.001), significantly lower activities VAS(pain during activities)scores...
Compared to sufentanil PCA, adding low dose of esketamine significantly reduced the consumption of sufentanil while providing equally effective post cesarean analgesia in the patients with gestational...
Managing acute postoperative pain is challenging for anesthesiologists, surgeons, and patients, leading to adverse events despite making significant progress. Patient-controlled intravenous analgesia ...
We performed a literature search in PubMed, Embase, the Cochrane Central Register of Controlled Trials, Web of Science, Chinese National Knowledge Infrastructure, Wanfang, and VIP databases up to Dece...
Fifteen RCTs were included in the meta-analysis. Compared with sufentanil, oxycodone showed lower Numerical Rating Scale scores (mean difference [MD] = -0.71, 95% confidence interval [CI]: -1.01 to -0...
Oxycodone improves postoperative analgesia and causes fewer adverse effects, and could be recommended for PCIA, especially after abdominal surgeries....
PROSPERO; https://www.crd.york.ac.uk/PROSPERO/; CRD42021229973....
Anxiety and pain commonly occur during nerve block, we aimed to investigate the sedation efficacy of different doses of remimazolam with sufentanil in young and elderly patients....
In this randomized trial, patients aged 18-85 years who underwent nerve block was enrolled. All patients received sufentanil 0.08 μg/kg for analgesia. Young patients (age < 65 years) were randomized i...
Ninety young and 114 elderly patients were enrolled, respectively. In comparison with Groups C and M, young patients in Group H had the highest success rate of procedure sedation (80.0 vs. 73.3 vs. 43...
Remimazolam 0.08 mg/kg provided the best sedation efficacy in young patients while remimazolam 0.04 mg/kg with the trend of less respiratory adverse events was more optimal for elderly patients....
http://www.chictr.org.cn/showproj.aspx?proj=122016 ....
To investigate the effect of sufentanil for spinal analgesia during cesarean section....
Eligible papers were systematically retrieved from PubMed, Embase, Ovid, and ScienceDirect. Two researchers independently extracted primary and secondary endpoints to compute relative risk and mean di...
A total of 8 publications with 503 pregnant women were included in this study for meta-analysis. Subarachnoid administration of sufentanil did not significantly reduce the onset time of sensory block ...
Subarachnoid administration of sufentanil has no significant difference in the combined effect value of shortening the onset time of sensory block and motor block, prolonging the onset time of local a...
Peripheral blocks are increasingly used for analgesia after video-assisted thoracic surgery (VATS). We hypothesised that addition of sufentanil and adrenaline to levobupivacaine would improve the anal...
We randomised 60 patients undergoing VATS to a 5-mL h...
At 48 h, the median cumulative PCA-morphine dose for the LB group was 6 mg (IQR, 2-10 mg) and for the LBSA group 7 mg (IQR, 3-13.5 mg; p = .378). At 72 h, morphine doses were 10 mg (IQR, 3-22 mg) and ...
For a continuous extrapleural block, and compared to plain levobupivacaine at 13.5 mg h...
This retrospective observational study aims to investigate the patient-controlled intravenous analgesia (PCIA) of dexmedetomidine (DEX) with nalbuphine (NAL) versus sufentanil (SUF) for post-cesarean ...
Sufentanil and ropivacaine when used as epidural anesthetics effectively reduce maternal pain during labor. From previous reports, rs2242480 single nucleotide polymorphisms (SNPs) can alter sufentanil...
We randomly divided 573 eligible mothers into groups A and B (in a 1 : 3 ratio). The control group (group A) was given sufentanil at the usual 0.5 mg/L-1 dose + 0.15% ropivacaine hydrochloride mixture...
Visual analog scale scores after analgesia across groups were significantly different from scores before analgesia, showing that analgesic effects across groups were effective. No significant differen...
We confirmed that individualizing sufentanil doses based on maternal genotypes increased safety and success rates for women during childbirth....
Cough is one of the most common complications following intravenous administration of sufentanil during anesthesia induction. The study aimed to investigate the protective effect of alfentanil, afenta...
Eighty patients that scheduled for thyroid surgery under general anesthesia were randomly divided into the alfentanil group and normal saline group, with 40 cases per group. Patients in the alfentanil...
The incidence of cough within one minute after the injection of sufentanil during anesthesia induction was 40% in the normal saline group, and the pretreatment of alfentanil significantly reduced the ...
Pretreatment with low-dose alfentanil (2 μg/kg) effectively and safely reduced both the incidence and severity of sufentanil-induced cough during anesthesia induction....
Chinese Clinical Trial Registry (identifier: ChiCTR2300069286)....
The results in Table 3 (highlighted) have been corrected to be consistent with the results reported in the text. Reference: YingHao Cao, Ping Chi, Chen Zhou, WenFei Lv, ZheFen Quan, Fu Shan Xue: Remim...
Sufentanil is used with ropivacaine in labor pain management but it can have respiratory depression. Dexmedetomidine is effective to maintain hemodynamic stability in parturient women and allow awake ...
Parturient women have received 0.125% ropivacaine with 0.5-μg/mL sufentanil (SR1 cohort, n = 115), or 0.08% ropivacaine with 0.5-μg/mL sufentanil (SR2 cohort, n = 109), or 0.125% ropivacaine with 0.5-...
At 2-h postpartum, the visual analog scale score of parturient women of the DR2 cohort was fewer than that of parturient women of the SR1 (p < 0.0001, q = 4.162) and the SR2 (p < 0.0001, q = 7.568) co...
Epidural 0.08% ropivacaine with 0.5-μg/mL dexmedetomidine is an effective and safe anesthetic regimen for hypertensive parturient women and their newborns....
III. Technical Efficacy Stage: 4....